Prognostic Factors and Therapy Assessment of IgA Nephropathy: Report from a Single Unit in Iran

Figures & data

Table 1. Demographic and clinical characteristics of patients with IgA nephropathy.

Characteristic	Measure
Number of patients	70
Age at renal biopsy, years	39 ± 12.1 (17–71)
Sex (men)	46
MAP, mmHg	103.6 ± 14.04 (78–134)
Arterial hypertension^a, yes (%)	25 (35.7)
Serum creatinine, mg/dL [median (IQR)]	1.6 (1–2.1)
Proteinuria, g/24 h [median (IQR)]	1829 (989–3611)
Histological grade (%)
I (mild)	12 (17.1)
II (moderate)	38 (54.3)
III (severe)	20 (28.6)
Progression to ESRD, no of cases (%)	10 (14.3)
Follow-up, months [median (range)]	23.5 (6–130)

Notes: MAP, mean arterial pressure; IQR, interquartile range; ESRD, end-stage renal disease.

^aMAP ≥ 107 mmHg.

Table 2. Demographic and clinical characteristics of IgA nephropathy patients with and without ESRD.

Characteristic	Non-ESRD patients	ESRD patients	p-Value
Number of patients	60	10
Age, years	37.9 ± 10.9	45.5 ± 16.8	0.065
Age ≥ 50, years	6 (10%)	6 (60%)	0.001
Sex (men)	37	9	0.081
Average MAP, mmHg	102.9±13.7	107.5±8.7	0.346
Hypertension^a, yes (%)	19 (31.7%)	6 (60%)	0.151
Grading (%)
I	12 (20)	0	<0.001
II	36 (60)	2 (20)
III	12 (20)	8 (80)
Serum creatinine, mg/dL [median (IQR)]	1.5 (1–2.02)	2.6 (1.6–4)	0.011
Proteinuria, g/24 h [median (IQR)]	1610 (742.5–2880)	3707 (3057–5967)	0.004

Notes: MAP, mean arterial pressure; IQR, interquartile range; ESRD, end-stage renal disease.

^aMAP ≥ 107 mmHg.

Figure 1. Kaplan–Meier renal survival curve of 70 patients with IgA nephropathy.

Table 3. Comparison of changes in proteinuria and GFR after 6 months of treatment with RAS inhibitors or combination therapy with prednisone.

	Baseline GFR > 30 mL/min and baseline proteinuria = 1–3 g/24 h			Baseline GFR > 30 mL/min and baseline proteinuria > 3 g/24 h
Characteristics	ACEIs/ARBs group (N = 9)	ACEIs/ARBs + steroid group (N = 20)	p-Value	ACEIs/ARBs group (N = 4)	ACEIs/ARBs + steroid group (N = 10)	p-Value
Age (year)	35 (25, 56)	38.5 (17, 56)	0.604	46 (25, 71)	38 (20, 70)	0.395
Sex (male)	3 (33.3%)	13 (65%)	0.226	2 (50%)	8 (80%)	0.520
Hypertension^a (yes)	1 (11.1%)	7 (35%)	0.371	2 (50%)	8 (80%)	0.520
Pathological grade	2 (1, 2)	2 (1, 3)	0.140	2.5 (2, 3)	2 (1, 3)	0.635
Baseline proteinuria (g/24 h)	1920 (1000, 2700)	1610 (1000, 2940)	1.0	3507.5 (3121, 5500)	4911 (3360, 11800)	1.0
6-month proteinuria (g/24 h)	324 (106, 1940)	320 (68, 2370)	0.637	312.5 (31, 5000)	1375 (420, 6000)	0.119
Δ Proteinuria^b (g/24 h)	−86.8 (−94.5, 49.2)	−74.7 (−97.2, 37.6)	0.962	−92.9 (−99.0, 42.2)	−73.6 (−92.7, 4.2)	0.203
Baseline GFR (mL/min)	75.3 (54.0, 137.0)	50.2 (30.1, 105.3)	0.003	54.7 (35.7, 99.5)	43.7 (30.5, 131.0)	0.572
6-month GFR (mL/min)	66.8 (58.7, 105.2)	60.9 (29.4, 135.5)	0.043	47.3 (7.4, 99.5)	62.1 (7.0, 114.3)	0.480
Δ GFR^c (mL/min)	−7.1 (−31.8, 46.9)	7.4 (−53.1, 78.8)	0.067	−2.2 (−38.6, 0)	12.7 (−47.5, 49.6)	0.055

Notes: Data are presented as median (minimum, maximum) and frequency (percent). GFR, glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

^aHypertension is defined as mean arterial pressure ≥ 107 mmHg.

^bΔ Proteinuria: difference between 6-month and baseline proteinuria.

^cΔ GFR: difference between 6-month and baseline GFR.